AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization

Jeremy O. Jones, W. Frank An, Marc I. Diamond

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Signaling via the androgen receptor (AR) plays an important role in human health and disease. All currently available anti-androgens prevent ligand access to the receptor, either by limiting androgen synthesis or by competitive antagonism at the ligand binding domain. It is unknown to what extent various steps of receptor activation may be separable and distinctly targeted by inhibitors. We have previously described the use of fluorescent protein fusions to AR to monitor its subcellular distribution and ligand-induced conformational change by fluorescence resonance energy transfer (FRET). We have now used a microscopy-based screen to identify inhibitors that prevent AR conformational change or nuclear accumulation after ligand activation. Hits were secondarily selected on the basis of their ability to inhibit AR transcription at a PSA-luciferase promoter and were tested for effects on 3H-DHT binding to AR in cells. We find a strong correlation between compounds that block DHT binding and those that inhibit nuclear accumulation. These compounds are structurally distinct from known antagonists. Additional compounds blocked AR conformational change but did not affect DHT binding or nuclear localization of AR. One compound increased ligand-induced FRET yet functioned as a potent inhibitor. These results suggest that multiple inhibitory conformations of AR are possible and can be induced by diverse mechanisms. The lead compounds described here may be candidates for the development of novel anti- androgens and may help identify new therapeutic targets.

Original languageEnglish (US)
Pages (from-to)199-208
Number of pages10
JournalACS Chemical Biology
Volume4
Issue number3
DOIs
StatePublished - Mar 20 2009

Fingerprint

Androgen Receptors
Microscopy
Microscopic examination
Throughput
Ligands
Androgens
Fluorescence Resonance Energy Transfer
Chemical activation
Lead compounds
Transcription
Luciferases
Conformations
Fusion reactions
Health

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. / Jones, Jeremy O.; An, W. Frank; Diamond, Marc I.

In: ACS Chemical Biology, Vol. 4, No. 3, 20.03.2009, p. 199-208.

Research output: Contribution to journalArticle

@article{1dca1aed59c84e67b8d07fa6f98b38fd,
title = "AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization",
abstract = "Signaling via the androgen receptor (AR) plays an important role in human health and disease. All currently available anti-androgens prevent ligand access to the receptor, either by limiting androgen synthesis or by competitive antagonism at the ligand binding domain. It is unknown to what extent various steps of receptor activation may be separable and distinctly targeted by inhibitors. We have previously described the use of fluorescent protein fusions to AR to monitor its subcellular distribution and ligand-induced conformational change by fluorescence resonance energy transfer (FRET). We have now used a microscopy-based screen to identify inhibitors that prevent AR conformational change or nuclear accumulation after ligand activation. Hits were secondarily selected on the basis of their ability to inhibit AR transcription at a PSA-luciferase promoter and were tested for effects on 3H-DHT binding to AR in cells. We find a strong correlation between compounds that block DHT binding and those that inhibit nuclear accumulation. These compounds are structurally distinct from known antagonists. Additional compounds blocked AR conformational change but did not affect DHT binding or nuclear localization of AR. One compound increased ligand-induced FRET yet functioned as a potent inhibitor. These results suggest that multiple inhibitory conformations of AR are possible and can be induced by diverse mechanisms. The lead compounds described here may be candidates for the development of novel anti- androgens and may help identify new therapeutic targets.",
author = "Jones, {Jeremy O.} and An, {W. Frank} and Diamond, {Marc I.}",
year = "2009",
month = "3",
day = "20",
doi = "10.1021/cb900024z",
language = "English (US)",
volume = "4",
pages = "199--208",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization

AU - Jones, Jeremy O.

AU - An, W. Frank

AU - Diamond, Marc I.

PY - 2009/3/20

Y1 - 2009/3/20

N2 - Signaling via the androgen receptor (AR) plays an important role in human health and disease. All currently available anti-androgens prevent ligand access to the receptor, either by limiting androgen synthesis or by competitive antagonism at the ligand binding domain. It is unknown to what extent various steps of receptor activation may be separable and distinctly targeted by inhibitors. We have previously described the use of fluorescent protein fusions to AR to monitor its subcellular distribution and ligand-induced conformational change by fluorescence resonance energy transfer (FRET). We have now used a microscopy-based screen to identify inhibitors that prevent AR conformational change or nuclear accumulation after ligand activation. Hits were secondarily selected on the basis of their ability to inhibit AR transcription at a PSA-luciferase promoter and were tested for effects on 3H-DHT binding to AR in cells. We find a strong correlation between compounds that block DHT binding and those that inhibit nuclear accumulation. These compounds are structurally distinct from known antagonists. Additional compounds blocked AR conformational change but did not affect DHT binding or nuclear localization of AR. One compound increased ligand-induced FRET yet functioned as a potent inhibitor. These results suggest that multiple inhibitory conformations of AR are possible and can be induced by diverse mechanisms. The lead compounds described here may be candidates for the development of novel anti- androgens and may help identify new therapeutic targets.

AB - Signaling via the androgen receptor (AR) plays an important role in human health and disease. All currently available anti-androgens prevent ligand access to the receptor, either by limiting androgen synthesis or by competitive antagonism at the ligand binding domain. It is unknown to what extent various steps of receptor activation may be separable and distinctly targeted by inhibitors. We have previously described the use of fluorescent protein fusions to AR to monitor its subcellular distribution and ligand-induced conformational change by fluorescence resonance energy transfer (FRET). We have now used a microscopy-based screen to identify inhibitors that prevent AR conformational change or nuclear accumulation after ligand activation. Hits were secondarily selected on the basis of their ability to inhibit AR transcription at a PSA-luciferase promoter and were tested for effects on 3H-DHT binding to AR in cells. We find a strong correlation between compounds that block DHT binding and those that inhibit nuclear accumulation. These compounds are structurally distinct from known antagonists. Additional compounds blocked AR conformational change but did not affect DHT binding or nuclear localization of AR. One compound increased ligand-induced FRET yet functioned as a potent inhibitor. These results suggest that multiple inhibitory conformations of AR are possible and can be induced by diverse mechanisms. The lead compounds described here may be candidates for the development of novel anti- androgens and may help identify new therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=65249138882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249138882&partnerID=8YFLogxK

U2 - 10.1021/cb900024z

DO - 10.1021/cb900024z

M3 - Article

VL - 4

SP - 199

EP - 208

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 3

ER -